BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 26595724)

  • 21. Cost-effectiveness of new antiviral regimens for treatment-naïve U.S. veterans with hepatitis C.
    Chidi AP; Rogal S; Bryce CL; Fine MJ; Good CB; Myaskovsky L; Rustgi VK; Tsung A; Smith KJ
    Hepatology; 2016 Feb; 63(2):428-36. PubMed ID: 26524695
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients.
    Younossi ZM; Singer ME; Mir HM; Henry L; Hunt S
    J Hepatol; 2014 Mar; 60(3):530-7. PubMed ID: 24269472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Cost-effectiveness analysis of sofosbuvir, peginterferon and ribavirin in patients with chronic hepatitis C: Early treatment in the initial stage of fibrosis vs. delayed treatment in advanced fibrosis].
    Buti M; Domínguez-Hernández R; Oyagüez I; Casado MÁ
    Gastroenterol Hepatol; 2016; 39(7):449-57. PubMed ID: 27084669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir.
    Younossi ZM; Stepanova M; Afdhal N; Kowdley KV; Zeuzem S; Henry L; Hunt SL; Marcellin P
    J Hepatol; 2015 Aug; 63(2):337-45. PubMed ID: 25795586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of treatment-naïve chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options.
    Cortesi PA; Ciaccio A; Rota M; Lim JK; De Salvia S; Okolicsanyi S; Vinci M; Belli LS; Mantovani LG; Strazzabosco M
    J Viral Hepat; 2015 Feb; 22(2):175-83. PubMed ID: 25040391
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Daclatasvir for the Treatment of Chronic Hepatitis C: A Critique of the Clinical and Economic Evidence.
    Llewellyn A; Faria R; Woods B; Simmonds M; Lomas J; Woolacott N; Griffin S
    Pharmacoeconomics; 2016 Oct; 34(10):981-92. PubMed ID: 27278217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic Evaluation of the Hepatitis C Virus Treatment Extension to Early-Stage Fibrosis Patients: Evidence from the PITER Real-World Cohort.
    Ruggeri M; Coretti S; Romano F; Kondili LA; Vella S; Cicchetti A
    Value Health; 2018 Jul; 21(7):783-791. PubMed ID: 30005750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The value of cure associated with treating treatment-naïve chronic hepatitis C genotype 1: Are the new all-oral regimens good value to society?
    Younossi ZM; Park H; Dieterich D; Saab S; Ahmed A; Gordon SC
    Liver Int; 2017 May; 37(5):662-668. PubMed ID: 27804195
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan.
    Kawaguchi I; Chayama K; Gonzalez YS; Virabhak S; Mitchell D; Yuen C; Kumada H
    Adv Ther; 2020 Jan; 37(1):457-476. PubMed ID: 31808054
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.
    Zhang S; Bastian ND; Griffin PM
    BMC Gastroenterol; 2015 Aug; 15():98. PubMed ID: 26239358
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis.
    Liu S; Watcha D; Holodniy M; Goldhaber-Fiebert JD
    Ann Intern Med; 2014 Oct; 161(8):546-53. PubMed ID: 25329202
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.
    Terrault NA; Zeuzem S; Di Bisceglie AM; Lim JK; Pockros PJ; Frazier LM; Kuo A; Lok AS; Shiffman ML; Ben Ari Z; Akushevich L; Vainorius M; Sulkowski MS; Fried MW; Nelson DR;
    Gastroenterology; 2016 Dec; 151(6):1131-1140.e5. PubMed ID: 27565882
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
    Hartwell D; Jones J; Baxter L; Shepherd J
    Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model.
    McEwan P; Kim R; Yuan Y
    Appl Health Econ Health Policy; 2013 Feb; 11(1):53-63. PubMed ID: 23329380
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis.
    Liu S; Cipriano LE; Holodniy M; Owens DK; Goldhaber-Fiebert JD
    Ann Intern Med; 2012 Feb; 156(4):279-90. PubMed ID: 22351713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of Egypt.
    Obach D; Deuffic-Burban S; Esmat G; Anwar WA; Dewedar S; Canva V; Cousien A; Doss W; Mostafa A; Pol S; Buti M; Siebert U; Fontanet A; Mohamed MK; Yazdanpanah Y
    Clin Infect Dis; 2014 Apr; 58(8):1064-71. PubMed ID: 24510934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
    Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
    JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients.
    Gimeno-Ballester V; Mar J; O'Leary A; Adams R; San Miguel R
    Expert Rev Gastroenterol Hepatol; 2017 Jan; 11(1):85-93. PubMed ID: 27500437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study.
    Abergel A; Asselah T; Metivier S; Kersey K; Jiang D; Mo H; Pang PS; Samuel D; Loustaud-Ratti V
    Lancet Infect Dis; 2016 Apr; 16(4):459-64. PubMed ID: 26803446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of Ledipasvir/Sofosbuvir and Predictors of Treatment Failure in Members with Hepatitis C Genotype 1 Infection: A Retrospective Cohort Study in a Medicaid Population.
    Kouris G; Hydery T; Greenwood BC; Lavitas P; Price M; Clements K; Alper CJ; Lenz K; Jeffrey PL
    J Manag Care Spec Pharm; 2018 Jul; 24(7):591-597. PubMed ID: 29952708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.